Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.

Abstract:

BACKGROUND:Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM:To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS:Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS:In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS:We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.

journal_name

Aliment Pharmacol Ther

authors

Joosse ME,Aardoom MA,Kemos P,Turner D,Wilson DC,Koletzko S,Martin-de-Carpi J,Fagerberg UL,Spray C,Tzivinikos C,Sladek M,Shaoul R,Roma-Giannikou E,Bronsky J,Serban DE,Ruemmele FM,Garnier-Lengline H,Veres G,Hojsak I,K

doi

10.1111/apt.14893

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

523-537

issue

5

eissn

0269-2813

issn

1365-2036

journal_volume

48

pub_type

杂志文章,多中心研究
  • Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.

    abstract:BACKGROUND:Strong suppression of viral replication and normalization of alanine aminotransferase is feasible with nucleos(t)ide analogues. It is estimated viral replication and liver inflammation can be controlled in 90% of patients with chronic hepatitis B with the current available treatments. AIM:To review the stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03481.x

    authors: Leemans WF,Ter Borg MJ,de Man RA

    更新日期:2007-12-01 00:00:00

  • Review article: gastrin releasing peptide and its value in assessing gastric secretory function.

    abstract::Gastrin releasing peptide (GRP) has proved to be a particularly valuable tool in detecting disturbances of gastric secretory function associated with duodenal ulcer disease and Helicobacter pylori infection, and it has furthered understanding of the pathophysiology of these conditions. Its attractiveness lies in the f...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1995.tb00392.x

    authors: McColl KE,el-Omar E

    更新日期:1995-08-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract:BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12908

    authors: Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期:2014-10-01 00:00:00

  • Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.

    abstract:BACKGROUND:Approximately 20% of primary sclerosing cholangitis (PSC) patients with concomitant inflammatory bowel disease (IBD) have Crohn's disease (CD). AIM:To compare PSC/CD with other PSC patients. METHODS:Retrospective study of 240 PSC patients diagnosed between 1975 and 2012 (median follow-up 12 years). Activit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13516

    authors: Fevery J,Van Steenbergen W,Van Pelt J,Laleman W,Hoffman I,Geboes K,Vermeire S,Nevens F

    更新日期:2016-03-01 00:00:00

  • The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.

    abstract:BACKGROUND:Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent. AIM:To conduct a meta-analysis to evaluate the efficacy of thymosin treatment in chronic hepatitis B virus infection. METHODS:Randomized controlled trials comparing thymosin for over ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.2001.01135.x

    authors: Chan HL,Tang JL,Tam W,Sung JJ

    更新日期:2001-12-01 00:00:00

  • Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation.

    abstract:AIM:To compare endoscopic banding ligation vs. no treatment in cirrhotics with intolerance or contraindications to beta-blockers for prevention of first bleeding in portal hypertension. METHODS:A sample size of 214 was planned with all sizes of varices. However, the trial was stopped due to increased bleeding in 52 pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2005.02457.x

    authors: Triantos C,Vlachogiannakos J,Armonis A,Saveriadis A,Kougioumtzian A,Leandro G,Manolakopoulos S,Tzourmakliotis D,Raptis SA,Burroughs AK,Avgerinos A

    更新日期:2005-06-15 00:00:00

  • Citric acid-enhanced Helicobacter pylori urease activity in vivo is unrelated to gastric emptying.

    abstract:BACKGROUND:In a previous study, the use of a citric acid test meal produced a rapid dose-dependent increase in urease activity that was significantly greater than that resulting from a pudding meal, ascorbic acid or sodium citrate. The mechanism was hypothesized to be related to the ability of citric acid to delay gast...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01096.x

    authors: Shiotani A,Saeed A,Yamaoka Y,Osato MS,Klein PD,Graham DY

    更新日期:2001-11-01 00:00:00

  • Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients.

    abstract:BACKGROUND:A simulated upper gastrointestinal (UGI) bleed in cirrhotic patients has been shown to induce hyperammonaemia. The kidney was the site of this exaggerated ammoniagenesis with alanine as substrate. Administration of alanine to decompensated cirrhotic patients did not change hepatic gluconeogenesis, but result...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2012.05044.x

    authors: Mpabanzi L,Deutz N,Hayes PC,Dejong CH,Olde Damink SW,Jalan R

    更新日期:2012-04-01 00:00:00

  • Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat.

    abstract:BACKGROUND:Many experiments have indicated that the gut glucagons (enteroglucagons) are associated with cell proliferation in the small intestine. However, recent studies have failed to show trophic effects of glicentin (enteroglucagon) on the intestine. AIMS:To examine the effects of glicentin on intestinal prolifera...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01082.x

    authors: Sasaki M,Fitzgerald AJ,Mandir N,Sasaki K,Wright NA,Goodlad RA

    更新日期:2001-10-01 00:00:00

  • Age-dependent eradication of Helicobacter pylori with dual therapy.

    abstract:BACKGROUND:Combined treatment using an acid-inhibiting drug with antibiotics can cure Helicobacter pylori infection. However, eradication rates are highly variable, especially if a proton pump inhibitor is used with amoxycillin. Therefore it is important to define factors/predictors of the clinical outcome. METHODS:In...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1997.00210.x

    authors: Treiber G,Ammon S,Klotz U

    更新日期:1997-08-01 00:00:00

  • Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).

    abstract:AIM:To define the characteristics of patients consulting with active dyspeptic symptoms in urban general practice, and to consider the implications of applying the British Society of Gastroenterology Dyspepsia management guidelines. DESIGN:Prospective observational study over a period of 12 months. SETTING:Two multip...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.00728.x

    authors: Bodger K,Eastwood PG,Manning SI,Daly MJ,Heatley RV

    更新日期:2000-04-01 00:00:00

  • Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.

    abstract:BACKGROUND:Gastrimmune is an immunogenic form of gastrin. It raises in situ antibodies against two proliferative forms of gastrin: amidated and glycine-extended gastrin-17. It has been shown to have a therapeutic action in several in vivo tumour models. Following immunization, due to the complex equilibrium that exists...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01081.x

    authors: Smith AM,Morris T,Justin T,Michaeli D,Watson SA

    更新日期:2001-12-01 00:00:00

  • Oral or intravenous erythromycin has no effect on human distal colonic motility.

    abstract::Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors. Its effect on pressure activity of the human colon has not been investigated. Eight healthy volunteers were studied on 2 occasions and given intravenous or ora...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1992.tb00573.x

    authors: Jameson JS,Rogers J,Misiewicz JJ,Raimundo AH,Henry MM

    更新日期:1992-10-01 00:00:00

  • Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites and the diagnosis of mixed ascites.

    abstract:BACKGROUND:The diagnostic value of ascitic cholesterol in the differential diagnosis of ascites is controversial. AIM:To investigate the diagnostic performance of ascitic cholesterol in the differential diagnosis of ascites. METHODS:Consecutive patients with new-onset ascites were enrolled prospectively. The pertinen...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15042

    authors: Du L,Zhu S,Lu Z,Xu T,Bai T,Xu D,Wei X,Li J,Xu K,Ye J,Hou X,Song Y

    更新日期:2019-01-01 00:00:00

  • Review article: indications for anti-reflux surgery and endoscopic anti-reflux procedures.

    abstract::Gastro-oesophageal reflux disease is a motor disorder principally caused by defective function of the lower oesophageal sphincter. Proton pump inhibitor (PPI) drugs alleviate symptoms, heal oesophagitis and improve quality of life but do not address the underlying motor disorder, and prolonged treatment is often neede...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02226.x

    authors: Palmer K

    更新日期:2004-12-01 00:00:00

  • Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.

    abstract:BACKGROUND:Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS:To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paedi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.14194

    authors: Lucendo AJ,Arias-González L,Molina-Infante J,Arias Á

    更新日期:2017-08-01 00:00:00

  • Review article: the opportunities and benefits of extended acid suppression.

    abstract::Acid suppression therapy with proton pump inhibitors is associated with well-established benefits in the management of gastro-oesophageal reflux (GERD) and other acid-related disorders. However, a number of issues still remain unsettled. Despite their clinical efficacy, when given once daily, currently available proto...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02945.x

    authors: Scarpignato C,Pelosini I

    更新日期:2006-06-01 00:00:00

  • Effect of omeprazole on lower oesophageal function in normal subjects.

    abstract::In a double-blind crossover study, lower oesophageal sphincter pressure (LOSP) and distal oesophageal motility were studied in eight healthy volunteers following a single intravenous dose of omeprazole or placebo. Lower oesophageal sphincter pressure was determined before and at intervals up to 120 min after intraveno...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1987.tb00648.x

    authors: Chakraborty TK,De Caestecker JS,Pryde A,Heading RC

    更新日期:1987-12-01 00:00:00

  • Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans.

    abstract:BACKGROUND:The role of 5-hydroxytryptamine in the control of gastric fundus tone in humans is still unknown. Selective 5-hydroxytryptamine re-uptake inhibitors act both centrally and peripherally to enhance the availability of physiologically released 5-hydroxytryptamine. AIM:To study the influence of a selective 5-hy...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01469.x

    authors: Tack J,Broekaert D,Coulie B,Fischler B,Janssens J

    更新日期:2003-02-15 00:00:00

  • Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.

    abstract:BACKGROUND:Approximately one third of patients with acute severe ulcerative colitis (ASUC) fail response to steroids. Ciclosporin and anti-TNFα are proven second-line therapies, but evidence of their efficacy has come mainly from tertiary centres and/or selective clinical trial recruitment. AIM:To assess ASUC outcomes...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12473

    authors: Lynch RW,Lowe D,Protheroe A,Driscoll R,Rhodes JM,Arnott ID

    更新日期:2013-10-01 00:00:00

  • Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies.

    abstract:BACKGROUND:Oesophagitis is usually a chronic condition. Healing with omeprazole is often followed by early relapse. Combination treatment and subsequent maintenance treatment with the prokinetic cisapride may be of benefit in relapse prevention. METHODS:Patients with endoscopically proven oesophagitis, grade I (n = 12...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1995.tb00382.x

    authors: Kimmig JM

    更新日期:1995-06-01 00:00:00

  • Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.

    abstract:BACKGROUND:Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. AIM:To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance. METHODS:We selected persons with (case-patients) and without (control-pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13621

    authors: Gounder PP,Bulkow LR,Snowball M,Negus S,Spradling PR,Simons BC,McMahon BJ

    更新日期:2016-06-01 00:00:00

  • Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2004.02294.x

    authors: Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

    更新日期:2005-01-01 00:00:00

  • Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules.

    abstract:BACKGROUND:4-Aminosalicylic acid has the potential for use in the treatment of diseases of the colon. AIM:To assess the feasibility of delivering 4-aminosalicylic acid directly to the colon using a hydroxypropylmethylcellulose capsule coated with a mixture of amylose, a polysaccharide metabolized by bacterial enzymes ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2002.01327.x

    authors: Tuleu C,Basit AW,Waddington WA,Ell PJ,Newton JM

    更新日期:2002-10-01 00:00:00

  • The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

    abstract:BACKGROUND:Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC). AIM:To review the safety profile of anti-TNF agents in all patients treated with infliximab in Edinburgh from 1999 to 2007. METHODS:Complete data were available on 202/207 patients comprising 157 CD, 42 UC and thre...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03882.x

    authors: Lees CW,Ali AI,Thompson AI,Ho GT,Forsythe RO,Marquez L,Cochrane CJ,Aitken S,Fennell J,Rogers P,Shand AG,Penman ID,Palmer KR,Wilson DC,Arnott ID,Satsangi J

    更新日期:2009-02-01 00:00:00

  • Review article: Long-term Helicobacter pylori infection--from gastritis to gastric cancer.

    abstract::An analysis carried out in 1994 by the WHO International Agency for Research on Cancer (IARC) resulted in Helicobacter pylori being designated as a Group 1 carcinogen and thus clearly having an association with the development of gastric cancer. In the case of H. pylori, the evaluation was made solely on the basis of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1998.00007.x

    authors: Asaka M,Kudo M,Kato M,Sugiyama T,Takeda H

    更新日期:1998-02-01 00:00:00

  • Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori.

    abstract:AIM:To identify optimal antibiotics for second-line quadruple therapy of Helicobacter pylori after failed 1-week triple therapy. METHODS:One hundred patients were enrolled in this study after the failure of 1-week triple therapy. They were randomized to receive 1-week quadruple therapy consisting of amoxicillin, omepr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01653.x

    authors: Chi CH,Lin CY,Sheu BS,Yang HB,Huang AH,Wu JJ

    更新日期:2003-08-01 00:00:00

  • Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells.

    abstract:BACKGROUND:Mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinases (ERK),c-Jun NH2-terminal kinases (JNK) and p38 MAP kinase (p38 MAPK) are important intermediates of the signal-transduction pathway from the cell surface to the nucleus. Expression of cyclooxygenase (COX)-2, associated ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01986.x

    authors: Tominaga K,Higuchi K,Sasaki E,Suto R,Watanabe T,Fujiwara Y,Oshitani N,Matsumoto T,Kim S,Iwao H,Arakawa T

    更新日期:2004-07-01 00:00:00

  • Short report: long-term management of peptic ulcer disease with ranitidine in Germany.

    abstract::One hundred and twenty-five patients with duodenal ulcer disease were given continuous ranitidine therapy after initial acute healing. Cumulative remission rates indicated that 95% of patients were ulcer-free after 1 year, 89% at 2 years, 81% at 3 years, 70% at 4 years and 60% at 5 and 6 years. Nine patients had a sec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2036.1994.tb00171.x

    authors: Simon B,Schütz E,Müller P,Dixon JS

    更新日期:1994-02-01 00:00:00

  • Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.

    abstract:BACKGROUND:Few studies have evaluated the effects of rabeprazole on low-dose aspirin (LDA)-induced gastroduodenal injuries. AIM:To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabepr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/apt.12907

    authors: Iwakiri R,Higuchi K,Kato M,Fujishiro M,Kinoshita Y,Watanabe T,Takeuchi T,Yamauchi M,Sanomura M,Nakagawa H,Sugisaki N,Okada Y,Ogawa H,Arakawa T,Fujimoto K

    更新日期:2014-10-01 00:00:00